Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

Hansoh Pharmaceutical

Biopharmaceutical company Antengene Corp. reported last Friday its net loss for the first half of 2023 widened 51.5% year-on-year to 144 million yuan.

FAST NEWS: Antengene’s loss widens on lower forex income, rising R&D costs

The latest: Biopharmaceutical company Antengene Corp. Ltd. (6996.HK) reported last Friday its net loss for the first half of 2023 widened 51.5% year-on-year to 144 million yuan ($19.8 million). Looking up: The…
August 28, 2023
6996.HK
Antengene announced Friday that it has entered into an exclusive collaboration agreement with Hansoh Pharmaceutical for the commercialization of the relapsed or refractory multiple myeloma drug Xpovio in mainland China.

FAST NEWS: Antengene appoints Hansoh to commercialize myeloma drug

The latest: Antengene Corporation Ltd. (6996.HK) announced Friday it has entered into an exclusive collaboration agreement with Hansoh Pharmaceutical Group Co. Ltd. (3692.HK) for the commercialization of the relapse or…
August 11, 2023
6996.HK

Recent Articles

Biopharmaceutical company Antengene Corp. reported last Friday its net loss for the first half of 2023 widened 51.5% year-on-year to 144 million yuan.
August 28, 2023

FAST NEWS: Antengene’s loss widens on lower forex income, rising R&D costs

6996.HK
August 11, 2023

FAST NEWS: Antengene appoints Hansoh to commercialize myeloma drug

6996.HK

RELATED ARTICLES

  1. Genfleet bio
    January 9, 2025
    Cancer drug maker Genfleet joins Hong Kong IPO influx
  2. January 24, 2025
    BeiGene heads for profit milestone after hemorrhaging cash
    6160.HK ONC.US 688235.SHG
  3. December 13, 2024
    Innogen Pharma jostles for a slice of the weight-loss market
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2025 Bamboo Works. All rights reserved.